Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ELVN vs SRRK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ELVN Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 5–2 Matrix Metrics)

ELVN Overall Winner 6-Pillar Tally: ELVN 3 – 1 SRRK (2 Tie) Matrix Metrics: ELVN 5 – 2 SRRK

As of Nov 16, 2026, Enliven Therapeutics, Inc. (ELVN) is the stronger overall head-to-head candidate over Scholar Rock Holding Corporation (SRRK) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ELVN carries a Unified Composite Score of 35.9/100 (SELL) at $47.54 (N/M Forward P/E, 0.0% operating margin), whereas SRRK carries 55.2/100 (HOLD) at $43.21 (N/M Forward P/E, -71732.3% operating margin).

  • Composite vs. Pillar Nuance: While SRRK currently prints a higher short-term Unified Composite Score (55.2/100 HOLD vs. ELVN 35.9/100 SELL), ELVN captures the overall institutional head-to-head verdict (5–2 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -71732.3% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY).
  • Technical & Structure Timing Caution: ELVN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.3); meanwhile SRRK is in a Breakdown options structure phase (RSI 45.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ELVN vs SRRK
ELVN NASDAQ Head-to-Head Winner
Enliven Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$47.54
-2.58% 1D
Market Cap $3.6B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.96β · 60% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 15.0 Fund 42.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.3 · SMA20: $45.78 · SMA50: $46.20
SRRK NASDAQ
Scholar Rock Holding Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$43.21
+0.01% 1D
Market Cap $5.3B
TTM Revenue $570,000
Forward P/E N/M
Beta / 30D Vol 1.02β · 61% Vol
Unified Composite Score
55.2 / 100 HOLD
Tech 48.0 Fund 59.0 Flow 64.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 45.9 · SMA20: $44.23 · SMA50: $45.89

6-Pillar Scorecard Institutional Category Breakdown (ELVN 3 – 1 SRRK)

Columns: Metric · ELVN · SRRK
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale SRRK
Revenue Growth (YoY) +0.0% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $570,000
Market Cap $3.6B $5.3B
3. Profitability & Quality ELVN
Gross Margin N/A N/A
Operating Margin 0.0% -71732.3%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -16.8% -200.0%
4. Balance Sheet & Cash Flow ELVN
Cash Generation (TTM) -$66M -$310M
Cash Flow Margin N/A N/A
Net Cash / Leverage $150M Net Cash $163M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ELVN
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 46.9% (5th %ile) 58.5% (7th %ile)
Put/Call OI Skew 1.67x (Put-Skewed) 0.53x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ELVN (5) vs SRRK (2)
Institutional Metric ELVN SRRK Criterion Row Edge
Market Capitalization
Scale
$3.6B $5.3B Larger Scale SRRK
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -100.0% Higher Growth ELVN
Operating Margin (TTM)
Profitability
0.0% -71732.3% Higher Margin ELVN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-16.8% -200.0% Higher ROE ELVN
52-Week Range Position
Momentum
69% ($15–$62) 43% ($29–$62) Stronger Trend ELVN
Beta / 30D Volatility
Risk Regime
0.96β · 60% Vol 1.02β · 61% Vol Lower Realized Risk ELVN
Unified Institutional Score
Composite Signal
35.9 / 100 (SELL) 55.2 / 100 (HOLD) Higher Composite SRRK
Trailing 12M Revenue (USD)
Operating Scale
N/A $570,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$66M ($150M Net Cash) -$310M ($163M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ELVN +19.08 pp
ELVN: +27.38% · SRRK: +8.3%
3M Horizon ELVN +0.17 pp
ELVN: -20.86% · SRRK: -21.03%
6M Horizon ELVN +28.76 pp
ELVN: +19.96% · SRRK: -8.8%
1Y Horizon ELVN +90.83 pp
ELVN: +134.53% · SRRK: +43.7%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ELVN vs SRRK. Trailing 12-month operating profitability (ELVN 0.0% vs SRRK -71732.3%) and valuation multiples (ELVN N/M vs SRRK N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ELVN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-16.8% · N/M
SRRK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$570,000
Gross MarginN/A
Op. Margin-71732.3%
ROE / Fwd P/E-200.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ELVN CONSOLIDATION
59d in phase · OBV NEUTRAL
Current IV 46.9%
IV Percentile 5th %ile
Put/Call OI Skew 1.67x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ELVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SRRK BREAKDOWN
57d in phase · OBV NEUTRAL
Current IV 58.5%
IV Percentile 7th %ile
Put/Call OI Skew 0.53x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SRRK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ELVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.6B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SRRK Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $5.3B market capitalization and -71732.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ELVN vs SRRK Key Questions & Quantitative Answers

As of Nov 16, 2026, Enliven Therapeutics, Inc. (ELVN) is the stronger overall head-to-head candidate over Scholar Rock Holding Corporation (SRRK) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ELVN carries a Unified Composite Score of 35.9/100 (SELL) at $47.54 (N/M Forward P/E, 0.0% operating margin), whereas SRRK carries 55.2/100 (HOLD) at $43.21 (N/M Forward P/E, -71732.3% operating margin). Composite vs. Pillar Nuance: While SRRK currently prints a higher short-term Unified Composite Score (55.2/100 HOLD vs. ELVN 35.9/100 SELL), ELVN captures the overall institutional head-to-head verdict (5–2 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -71732.3% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY). Technical & Structure Timing Caution: ELVN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.3); meanwhile SRRK is in a Breakdown options structure phase (RSI 45.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SRRK leads the Growth & Scale pillar: ELVN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SRRK at -100.0% YoY revenue growth and +0.0% YoY earnings growth on $570,000 TTM revenue (N/A gross margin, -71732.3% operating margin). On trailing 12-month operating scale, ELVN generates N/A in USD-normalized revenue versus $570,000 for SRRK. In operating R&D and SG&A reinvestment, ELVN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SRRK.

ELVN and SRRK trade at balanced relative valuation multiples. ELVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas SRRK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ELVN (-16.8% ROE) versus SRRK (-200.0% ROE) capital efficiency.

In options market volatility and institutional positioning, ELVN carries 46.9% implied volatility (5th %ile, Compressed (<25th %ile)), a 1.67x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.96β · 60% Vol realized risk). By comparison, SRRK carries 58.5% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.53x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.02β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.